Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2025 Rev YoY: +11.9% EPS YoY: +150.8% Move: -0.15%

Champions Oncology Inc

CSBR

$6.54 -0.15%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q1 2025

Published: Sep 13, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for CSBR

Reported

Report Date

Sep 13, 2024

Quarter Q1 2025

Revenue

14.06M

YoY: +11.9%

EPS

0.09

YoY: +150.8%

Market Move

-0.15%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $14.06M up 11.9% year-over-year
EPS of $0.09 increased by 150.8% from previous year
Gross margin of 49.7%
Net income of 1.31M
"“The positive momentum which began last quarter has continued. We have begun the year with another good revenue quarter, in excess of $14 million, improved operational efficiency and scalability, all leading to expanded profitability.”" - Ronnie Morris

CSBR

Company CSBR

Period Q1 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 10, 2026

Executive Summary

Champions Oncology reported a solid start to FY2025 with Q1 QQ1 2025 revenue of $14.061 million, up 11.9% year over year, supported by ongoing operational improvements and a higher revenue conversion rate. Gross margin expanded to 49.7% (approx. 50%), as cost of sales declined to $7.072 million from $7.5 million a year earlier, underscoring efficiency gains in service delivery. Net income reached $1.313 million with GAAP operating income of $1.329 million and EBITDA of $1.778 million; adjusted EBITDA was $2.0 million, marking a positive earnings trajectory versus prior-year losses. Management characterized the quarter as a continuation of a turnaround that began in the prior year, aided by scalable platforms (PDX bank, in vivo/ex vivo platforms) and a renewed emphasis on cost discipline.

Key Performance Indicators

Revenue

Increasing

14.06M

QoQ: 0.43% | YoY: 11.94%

Gross Profit

Increasing

6.99M

49.70% margin

QoQ: 3.53% | YoY: 43.31%

Operating Income

Increasing

1.33M

QoQ: 710.37% | YoY: 152.08%

Net Income

Increasing

1.31M

QoQ: 1 304.59% | YoY: 151.17%

EPS

Increasing

0.10

QoQ: 1 307.50% | YoY: 150.84%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $14.061 million; YoY +11.94%; QoQ +0.43%. GrossProfit: $6.989 million; GrossMargin = 49.7%; YoY +43.31%; QoQ +3.53%. OperatingIncome: $1.329 million; Margin = 9.45%; YoY +152.08%; QoQ +710.37%. NetIncome: $1.313 million; NetMargin = 9.34%; YoY +151.17%; QoQ +1304.59%. EPS: $0.0966; Diluted $0.0935; YoY +150.84%; QoQ +1307.50%. EBITDA: $1.778 million; EBITDA Margin = 12.64%. Adjusted EBITDA: $2.0 million (vs. prior-year adjusted loss). CostOfSales: $7.072 million; R&D: $1.454 million; SG&A (Selling, General & Administrative): $4.206 million; R&D decline vs year-ago period (~$1.3 million reduction). OperatingExpenses: $5.66 million; Depreciation & Amortization: $0.449 million. CashFlow: Operating cash flow $0.311 million; Free cash flow $0.311 million. Balance Sheet: Cash and equivalents $2.89 million; Total Debt $7.107 million; NetDebt $4.215 million; TotalAssets $24.933 million; TotalLiabilities $25.265 million; Stockholders’ Equity = -$0.332 million. Liquidity: CurrentRatio 0.688; QuickRatio 0.688; CashRatio 0.151; DSO ~57.8 days; CCC = -8.81 days.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	14.06M	11.94%	0.43%
Gross Profit	6.99M	43.31%	3.53%
Operating Income	1.33M	152.08%	710.37%
Net Income	1.31M	151.17%	1 304.59%
EPS	0.10	150.84%	1 307.50%

Key Financial Ratios

Gross Profit Margin

Good

49.70%

Gross profit margin is healthy and competitive within industry standards

Operating Profit Margin

Fair

9.45%

Operating margin is moderate, room for improvement in cost management

Net Profit Margin

Fair

9.34%

Net profit margin is moderate, room for improvement in cost management

Return on Assets

Fair

5.27%

Return on assets is acceptable but below top-tier companies

Return on Equity

Weak

-3.95%

Return on equity suggests inefficient capital allocation

Current Ratio

Concern

0.69

Current ratio below safe levels, potential liquidity risk

Debt to Equity

Conservative

-21.41

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Value

12.40x

P/E ratio suggests potential undervaluation or stable earnings

Price to Book

Undervalued

-196.13x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2026	0.00	0.02	+0.0%	View
Q1 2026	0.00	-0.03	+0.0%	View
Q3 2025	17.04	0.31	+41.8%	View
Q2 2025	13.49	0.05	+16.6%	View
Q1 2025	14.06	0.09	+11.9%	View

CSBR

Champions Oncology Inc

Q2 2026 Report

Champions Oncology Inc (CSBR) QQ2 2026 Earnings Analysis: Modest profitability amid negative gross margin, strong deferred revenue, and measured liqui...

Read full report

CSBR

Champions Oncology Inc

Q1 2026 Report

Champions Oncology Inc (CSBR) QQ1 2026 Results – Cash-Flow Resilience Amid Revenue Disclosure Gap...

Read full report

CSBR

Champions Oncology Inc

Q3 2025 Report

Champions Oncology Inc (CSBR) QQ3 2025 Earnings Analysis: Record Quarter with Data Licensing Milestone and Margin Expansion...

Read full report

CSBR

Champions Oncology Inc

Q2 2025 Report

Champions Oncology Inc (CSBR) Q2 2025 Results: Revenue Growth Driven by Core Services and a Strategic Data Licensing Push...

Read full report

Champions Oncology Inc (CSBR) Q1 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More CSBR Quarterly Reports

CSBR

CSBR

CSBR

CSBR

Q1 2025 Reports in Healthcare Sector

ANEB

Related Financial Data

Sector Analysis: Healthcare

CSBR Full Profile

CSBR Financial Statements

Earnings Calendar